How Clinical Trials Work

• A. To sell a new drug to the public as quickly as possible
• B. To determine whether a medical treatment, device, or intervention is safe and effective in people ✓
• C. To replace the need for doctors in patient care
• D. To collect personal health data for insurance companies

Why: Clinical trials are research studies designed to evaluate whether a treatment, device, or intervention is safe and effective for people, generating evidence that guides medical decisions.

• A. To give participants extra medication for free
• B. To provide a comparison so researchers can tell whether the treatment itself caused any observed effects ✓
• C. To make the study cheaper by reducing the number of participants
• D. To ensure all participants receive the newest treatment

Why: A control group receives a placebo or standard care, allowing researchers to compare outcomes and determine whether the treatment being tested actually makes a difference.

• A. Participants choose which treatment they want to receive
• B. Participants are assigned to treatment groups by chance rather than by researcher or participant preference ✓
• C. The study results are determined by drawing numbers from a hat after the trial ends
• D. Only healthy volunteers are allowed to join the study

Why: Randomization assigns participants to groups by chance, which helps reduce bias and makes it more likely that differences in outcomes are due to the treatment rather than other factors.

• A. A payment agreement between the participant and the drug company
• B. The process of giving participants clear information about the study so they can voluntarily decide whether to take part ✓
• C. A guarantee that the treatment will work for the participant
• D. A form signed by the doctor confirming the trial has been approved

Why: Informed consent means participants receive understandable information about the study's purpose, risks, benefits, and alternatives, and they can choose to join or leave the study voluntarily.

• A. Laboratory and animal studies are always inaccurate and therefore useless
• B. Results from lab and animal studies do not always predict how a treatment will work in humans, so testing in people is necessary ✓
• C. Regulators require trials only for marketing purposes
• D. Clinical trials are only needed for treatments that cost more than a certain amount

Why: Lab and animal results are valuable starting points but often do not translate directly to humans, so clinical trials are essential to confirm safety and effectiveness in the people who will actually use the treatment.

• A. To determine whether the treatment is more effective than the current standard of care
• B. To assess safety and identify the appropriate dose in a small group of participants ✓
• C. To confirm long-term side effects in thousands of patients
• D. To compare the drug's price with competing products on the market

Why: Phase 1 trials typically enroll a small number of participants (often 20-100 healthy volunteers or patients) to evaluate safety, tolerability, and dosing, and to learn how the drug is absorbed and eliminated by the body.

• A. Phase 1
• B. Phase 2
• C. Phase 3 ✓
• D. Phase 0

Why: Phase 3 trials are the largest, often enrolling hundreds to thousands of participants, so researchers can confirm effectiveness, monitor side effects, and compare the treatment against standard care or placebo.

• A. Phase 1
• B. Phase 2 ✓
• C. Phase 4
• D. Preclinical testing

Why: Phase 2 trials involve several dozen to a few hundred participants with the condition being studied. Their main aim is to get an initial sense of whether the treatment works while continuing to monitor safety.

• A. To find the first safe dose in humans
• B. To monitor long-term safety and effectiveness after the drug has been approved ✓
• C. To test whether a drug works in animals
• D. To determine the initial manufacturing process

Why: Phase 4 trials, also called post-marketing surveillance studies, occur after regulatory approval. They gather information about long-term risks, rare side effects, and how the treatment performs in broader real-world populations.

• A. To delay the release of new medicines for financial reasons
• B. To reduce risk to participants by gathering safety data step by step before expanding testing ✓
• C. Because each phase is required only in certain countries
• D. To avoid the need for informed consent in later phases

Why: Testing in stages allows researchers to catch safety problems early when fewer people are exposed, and to refine dosing and study design before committing to large, costly, and longer studies.

• A. To give every participant the newest treatment available
• B. To provide a comparison group so researchers can tell whether the intervention itself caused any observed effects ✓
• C. To reduce the total number of participants needed for the study
• D. To ensure that all participants receive the same dose of medication

Why: A control group receives no intervention, a placebo, or the standard treatment, which allows researchers to separate the effect of the intervention from natural disease progression, placebo effects, and other factors.

• A. It guarantees that the treatment group will be healthier than the control group
• B. It allows participants to choose which group they prefer
• C. It helps distribute known and unknown confounding factors evenly between groups, reducing selection bias ✓
• D. It makes it possible to skip the use of a control group

Why: Random assignment gives each participant an equal chance of being placed in any group, so differences in age, severity, or other characteristics are likely to balance out across groups, making the groups comparable.

• A. Only the statistician analyzing the data
• B. Only the study participants ✓
• C. Only the researchers who enroll participants
• D. Neither the participants nor the investigators

Why: In a single-blind design, participants do not know whether they receive the active treatment or the control, while the investigators know the assignments. Double-blind studies hide assignments from both participants and investigators.

• A. Placebos are cheaper than all other treatments
• B. Placebos are required by law for every trial
• C. Placebos make participants feel they are receiving an active drug, which helps separate the true drug effect from the psychological effect of receiving treatment ✓
• D. Placebos cure the disease being studied

Why: A placebo is an inactive substance that looks like the real treatment. It accounts for the placebo effect, where expectations alone can change how participants feel or respond, so researchers can measure the drug's true effect.

• A. Participants will refuse to join the study
• B. Knowledge of the assigned treatment may bias how participants report symptoms or how researchers assess outcomes ✓
• C. The trial will always produce negative results
• D. Randomization becomes impossible to perform

Why: When everyone knows who receives which treatment, expectations can influence subjective outcomes such as pain reports or quality of life ratings, and researchers may unconsciously treat groups differently. Blinding helps reduce this bias.

• A. To collect the participant's medical records for the study sponsor
• B. To ensure participants understand the study's purpose, procedures, risks, and benefits before voluntarily agreeing to take part ✓
• C. To guarantee that participants will receive the experimental treatment
• D. To transfer legal responsibility for any adverse events from the investigator to the participant

Why: Informed consent is a process that protects participant autonomy. Participants must understand what the study involves, including its risks and benefits, and must voluntarily agree to join. It does not guarantee treatment assignment or shift responsibility away from investigators.

• A. Participants may be required to join if their doctor recommends it
• B. Participants can decline to join or withdraw at any time without penalty or loss of their usual care ✓
• C. Participants must remain in the study until it is completed
• D. Participants are paid only if they complete every study visit

Why: Participation must be voluntary, meaning people can say no or leave the study at any point without losing access to standard medical care or other benefits they would otherwise receive.

• A. Because the sponsor needs the signed form to receive funding
• B. Because screening and enrollment procedures cannot be billed to insurance without a signature
• C. Because participants must be able to make an informed decision before undergoing any research-related activity ✓
• D. Because consent forms are only valid if signed on the day of the first dose

Why: Research procedures, even screening tests, should not begin until the person has given informed consent, so that they can make an informed decision about whether to take part.

• A. A guarantee that the new treatment will be more effective than existing options
• B. A description of the study's alternatives, including standard treatment options available outside the trial ✓
• C. The investigator's personal financial interest in the drug
• D. A list of other participants' names and medical histories

Why: Consent documents must explain reasonable alternatives, such as standard care, so participants can compare their options. They must not promise benefits or disclose other participants' private information.

• A. Emphasize the benefits of the study while downplaying its risks to increase enrollment
• B. Offer generous incentives that might pressure people into joining despite concerns
• C. Provide accurate, balanced information and give people adequate time to consider the decision ✓
• D. Enroll people immediately during the first conversation to avoid losing them to other studies

Why: Ethical recruitment requires honest, balanced information and enough time for reflection. Downplaying risks, pressuring people, or rushing enrollment undermines voluntary, informed decision-making.

• A. To market new drugs to physicians
• B. To review and approve research protocols to protect the rights and welfare of participants ✓
• C. To set the price of approved medications
• D. To manufacture investigational products for trials

Why: An IRB (or ethics committee) independently reviews study protocols, consent materials, and risks before a trial begins, and monitors ongoing research to ensure participants are protected.

• A. Only a signature on a single form
• B. Agreement from a family member on their behalf
• C. A clear explanation of the study's purpose, risks, benefits, and alternatives, with the participant's voluntary agreement ✓
• D. Payment of a refundable deposit

Why: Informed consent is an ongoing process in which participants receive understandable information about the study and can voluntarily decide whether to take part, and they may withdraw at any time.

• A. Autonomy
• B. Justice ✓
• C. Beneficence
• D. Confidentiality

Why: The principle of justice requires that the burdens and benefits of research be distributed fairly, so no group is exploited or unfairly selected for risk.

• A. To handle the trial's advertising budget
• B. To periodically review accumulating trial data for safety concerns and advise whether the study should continue, be modified, or stop ✓
• C. To decide which drug company receives the patent
• D. To enroll new participants after the trial ends

Why: A DSMB is an independent group of experts that monitors participant safety and interim results, and can recommend stopping a trial early if harm is evident or benefit is clear.

• A. Once enrolled, participants must complete the full study
• B. Participants may withdraw from the study at any time without penalty or loss of ordinary medical care ✓
• C. Participants must pay for any study-related treatment they receive
• D. Participants lose access to their medical records during the trial

Why: Voluntary participation includes the right to withdraw at any time without losing access to standard care or other benefits to which they are entitled.

• A. To determine the cost of the study drug
• B. To measure whether the intervention produces the expected outcomes compared with a control ✓
• C. To select the marketing strategy for the new treatment
• D. To decide which hospitals will participate in future trials

Why: Clinical trials collect data on outcomes such as safety and efficacy so researchers can evaluate whether the intervention works, typically by comparing it against a control group.

• A. The last participant to enroll in the study
• B. The main outcome measure the trial is designed to evaluate ✓
• C. The date on which data collection ends for all sites
• D. The final report submitted to regulators

Why: The primary endpoint is the pre-specified main outcome that the trial is powered to assess, such as survival or reduction in blood pressure.

• A. To store patient genetic samples
• B. To standardize how data is recorded for each participant ✓
• C. To advertise the trial to potential volunteers
• D. To calculate the trial's budget

Why: A case report form provides a structured, consistent way to record each participant's data, which helps ensure accuracy and comparability across sites.

• A. Removing all patient identifiers from the dataset
• B. Keeping participants, investigators, or assessors unaware of treatment assignments to reduce bias ✓
• C. Analyzing data only from the first month of the trial
• D. Excluding participants who experience side effects

Why: Blinding prevents knowledge of the assigned treatment from influencing how participants report outcomes or how investigators assess them, reducing bias.

• A. Only participants who completed the full study are analyzed
• B. Participants are analyzed in the groups they were originally randomized to, regardless of whether they followed the protocol ✓
• C. Only participants who dropped out early are analyzed
• D. Data is analyzed according to the treatment each participant actually received

Why: Intention-to-treat analysis keeps participants in their randomized groups, preserving the benefits of randomization and giving a more realistic estimate of treatment effect in practice.

• A. There is a 97% chance the treatment works
• B. If there were truly no effect, results at least this extreme would occur about 3% of the time ✓
• C. The treatment is 3% more effective than placebo
• D. 3% of participants experienced side effects

Why: A p-value is the probability of observing results at least as extreme as those seen, assuming the null hypothesis (no true effect) is correct. It does not measure the probability that the treatment works or the size of the effect.

• A. The treatment reduces risk by 95%
• B. The true effect is plausibly somewhere between a 1.2 and 2.5 fold increase in risk, and the estimate is statistically significant because the interval excludes 1 ✓
• C. There is a 95% chance the result is wrong
• D. The trial enrolled 95 participants

Why: A confidence interval gives a range of plausible values for the true effect. Because this interval does not include 1 (the value meaning no difference for a ratio), the result is statistically significant at the 5% level.

• A. To save money on active medications
• B. To make participants feel they are receiving treatment
• C. To separate the effects of the treatment from expectations, the natural course of illness, and other non-specific influences ✓
• D. To ensure all participants experience side effects so safety can be measured

Why: A placebo group lets researchers compare outcomes with and without the active treatment while holding expectation effects and natural disease fluctuation roughly constant, so any remaining difference can be attributed to the treatment.

• A. To choose the fastest participants for the study
• B. To balance known and unknown factors between groups so differences in outcomes are more likely due to the treatment ✓
• C. To make the trial shorter
• D. To ensure the sponsor's preferred treatment is assigned to healthier patients

Why: Random assignment helps ensure that groups are comparable at baseline, including for factors researchers did not measure, which makes it more credible that outcome differences reflect the intervention rather than pre-existing differences.

• A. 50%
• B. 5 percentage points ✓
• C. 5%
• D. 15 percentage points

Why: Absolute risk reduction is the simple difference in event rates: 10% minus 5% equals 5 percentage points. The relative risk reduction would be 50%, which sounds larger but describes the same result.